Are All Dopamine Agonists Essentially the Same?
- Published in:
- Drugs, 2019, v. 79, n. 7, p. 693, doi. 10.1007/s40265-019-01103-2
- By:
- Publication type:
- Article
Works matching AU Torti, Margherita
Results: 15
1
2
Therapeutic education for empowerment and engagement in patients with Parkinson's disease: A non-pharmacological, interventional, multicentric, randomized controlled trial.
- Published in:
- Frontiers in Neurology, 2023, p. 1, doi. 10.3389/fneur.2023.1167685
- By:
- Publication type:
- Article
3
Anorectal function in multiple system atrophy and Parkinson's disease.
- Published in:
- 2000
- By:
- Publication type:
- journal article
4
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
- Published in:
- Drug Design, Development & Therapy, 2016, v. 10, p. 609, doi. 10.2147/DDDT.S77749
- By:
- Publication type:
- Article
5
An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson's disease.
- Published in:
- Expert Opinion on Pharmacotherapy, 2021, v. 22, n. 8, p. 965, doi. 10.1080/14656566.2021.1895748
- By:
- Publication type:
- Article
6
Istradefylline for the treatment of Parkinson’s disease: is it a promising strategy?
- Published in:
- Expert Opinion on Pharmacotherapy, 2018, v. 19, n. 16, p. 1821, doi. 10.1080/14656566.2018.1524876
- By:
- Publication type:
- Article
7
Advances in dopamine receptor agonists for the treatment of Parkinson’s disease.
- Published in:
- Expert Opinion on Pharmacotherapy, 2016, v. 17, n. 14, p. 1889, doi. 10.1080/14656566.2016.1219337
- By:
- Publication type:
- Article
8
Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's disease.
- Published in:
- Expert Opinion on Drug Metabolism & Toxicology, 2018, v. 14, n. 12, p. 1189, doi. 10.1080/17425255.2018.1550483
- By:
- Publication type:
- Article
9
Non motor symptoms in progressive supranuclear palsy: prevalence and severity.
- Published in:
- NPJ Parkinson's Disease, 2017, v. 3, n. 1, p. N.PAG, doi. 10.1038/s41531-017-0037-x
- By:
- Publication type:
- Article
10
Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar).
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 11, p. 2605, doi. 10.1111/bcp.14086
- By:
- Publication type:
- Article
11
Continuous Levodopa Delivery with an Intraoral Micropump System: An Open‐Label Pharmacokinetics and Clinical Study.
- Published in:
- Movement Disorders, 2024, v. 39, n. 6, p. 945, doi. 10.1002/mds.29824
- By:
- Publication type:
- Article
12
Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
13
Safety considerations when using non-ergot dopamine agonists to treat Parkinson's disease.
- Published in:
- Expert Opinion on Drug Safety, 2020, v. 19, n. 9, p. 1155, doi. 10.1080/14740338.2020.1804550
- By:
- Publication type:
- Article
14
L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson’s Disease: A Randomised Study.
- Published in:
- Parkinson's Disease (20420080), 2015, v. 2015, p. 1, doi. 10.1155/2015/369465
- By:
- Publication type:
- Article
15
Effect of family history, occupation and diet on the risk of Parkinson disease: A case-control study.
- Published in:
- PLoS ONE, 2020, v. 15, n. 12, p. 1, doi. 10.1371/journal.pone.0243612
- By:
- Publication type:
- Article